An injectable peptide product has to be sterile, isotonic, and stable in solution or readily reconstitutable, and those three requirements frequently conflict.
Key Takeaways
- Peptides cannot be terminally sterilised by autoclaving, so sterile filtration through a membrane is the standard route.
- Solution presentations are convenient but usually less stable, while lyophilised material requires reconstitution but stores better.
- The vial, stopper, and any lubricant on the closure can leach material into the formulation.
Sterility without heat
Peptides cannot be terminally sterilised by autoclaving, so sterile filtration through a membrane is the standard route. Filter compatibility matters because peptides adsorb to some membrane materials, and recovery must be checked rather than assumed.
Isotonicity and pH
Sodium chloride, mannitol, or glycerol adjusts tonicity, and the target is physiological range to avoid discomfort at the injection site. The pH must sit within a tolerable window while remaining at a point where the peptide is stable, which is not always the same value.
For related mechanism work, see oral peptide bioavailability.
Solution versus lyophilised presentation
Solution presentations are convenient but usually less stable, while lyophilised material requires reconstitution but stores better. The decision is driven by demonstrated stability rather than by convenience.
Preservation for multi-dose
Multi-dose vials require an antimicrobial preservative, and common options include phenol, m-cresol, and benzyl alcohol. Each interacts with the peptide and must be tested for compatibility rather than assumed inert.
Extractables and container closure
The vial, stopper, and any lubricant on the closure can leach material into the formulation. Container-closure compatibility is part of the stability programme and is a common late-stage source of surprises.
Experimental Conditions and Practical Setup
Sterile filtration is followed by a recovery check, because peptides adsorb to some membrane materials and the loss can be significant at low concentration. Filter compatibility is tested on the actual formulation, and the first portion of filtrate is often discarded or the filter is pre-conditioned to reduce adsorptive loss.
Injectable presentation requirements
| Requirement | Typical approach | Conflict to watch |
|---|---|---|
| Sterility | Membrane filtration | Adsorptive loss of peptide |
| Isotonicity | Sodium chloride, mannitol, glycerol | May affect stability |
| pH | Buffer within tolerable window | Tolerable pH may not be optimal pH |
| Multi-dose preservation | Phenol, m-cresol, benzyl alcohol | Preservative-peptide interaction |
Practical Notes for the Bench
- Check peptide recovery after sterile filtration rather than assuming it.
- Test preservative compatibility with the specific peptide.
- Include container-closure compatibility in the stability programme.
Frequently Asked Questions
Can peptides be autoclaved?
No. Sterile filtration is the standard approach because thermal sterilisation would degrade the peptide.
Which preservative should I use?
Phenol, m-cresol, and benzyl alcohol are common, but compatibility must be demonstrated for each peptide.
Why is lyophilised material preferred?
Because stability in the dry state is generally far better than in solution, at the cost of requiring reconstitution.
Why are peptides not terminally sterilised by autoclaving?
Because thermal sterilisation would degrade the molecule. Sterile filtration is the standard route, with recovery verified afterwards.
Related Reading
- oral peptide bioavailability
- peptide excipient compatibility
- peptide pH stability
- SS-31 elamipretide
- natriuretic peptides
References & Further Reading
- Butreddy A et al. PLGA/PLA-Based Long-Acting Injectable Depot Microspheres in Clinical Use: Production and Characterization Overview for Protein/Peptide Delivery. Int J Mol Sci. 2021. PubMed 34445587
- Meier JJ et al. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Front Endocrinol (Lausanne). 2021. PubMed 34248838
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Priya Raghunathan, MSc, Formulation & Stability Science.